Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
about
Methotrexate for maintenance of remission in ulcerative colitisMethotrexate for induction of remission in ulcerative colitisMethotrexate for induction of remission in refractory Crohn's diseaseMethotrexate for induction of remission in refractory Crohn's diseaseMethotrexate for maintenance of remission in ulcerative colitisMethotrexate for induction of remission in ulcerative colitisMethotrexate for induction of remission in refractory Crohn's diseaseOptimal management of steroid-dependent ulcerative colitisOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseImpact of medical therapies on inflammatory bowel disease complication rateSevere and steroid-resistant Crohn's diseaseMethotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin.Efficacy of parenteral methotrexate in refractory Crohn's disease.Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.Limitations in assessment of mucosal healing in inflammatory bowel diseaseUsing the Children's Depression Inventory in youth with inflammatory bowel disease: support for a physical illness-related factorRate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.How to do without steroids in inflammatory bowel disease.Efficacy of methotrexate in ulcerative colitis: failure or promise.European evidence-based Consensus on the management of ulcerative colitis: Current management.Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.Comparative tolerability of treatments for inflammatory bowel disease.Maintenance of optimal vitamin D status in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing two regimens.Pulmonary manifestations of inflammatory bowel diseaseMethotrexate: underused and ignored?Pulmonary manifestations of Crohn's disease.Drug therapy of ulcerative colitisUlcerative colitis: current treatment strategies and future prospects.Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.Risk-benefit assessment of methotrexate in the treatment of severe psoriasis.Pharmacokinetic considerations in the treatment of inflammatory bowel disease.Methotrexate for Inflammatory Bowel Diseases - New DevelopmentsCombination therapy using fexofenadine, disodium cromoglycate, and a hypoallergenic amino acid-based formula induced remission in a patient with steroid-dependent, chronically active ulcerative colitis.Review article: monitoring for drug side-effects in inflammatory bowel disease.The efficacy of methotrexate for maintaining remission in inflammatory bowel disease.Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease.Review article: medical treatment of active Crohn's disease.Ulcerative colitis in children: medical management.Methotrexate for induction of remission in refractory Crohn's disease.Review article: medical treatment of moderate to severe Crohn's disease.
P2860
Q24187928-BF98509C-78EE-400E-8CEE-30571DAEED0EQ24194275-79B888F6-5985-4091-98FF-76917B327054Q24194453-A508327C-EDF0-4EA8-87DA-EDFA45432AB3Q24202436-0938FB98-90A8-4B1B-9B46-7E59C1FD7BFBQ24240019-725BBD3A-B405-4179-8E1D-15634C3583ADQ24243284-3BE63E75-D232-4454-881C-9641433FEDE5Q24245655-DC5D28BA-BA09-4337-A236-5466541459A8Q26773203-732C60DA-E378-43B2-BCF1-F59876A7E1F7Q26866940-2E1925CF-991C-4476-B0A8-E90D8C40B6E3Q26995479-FED927AE-0CE4-4AA1-8DC0-FC90955DBF5DQ28266806-D3869BEF-CBB4-47D8-89D3-F725C62F053DQ31082605-0A096193-CA1C-46EE-AD59-65D647917EEBQ31795133-B49C7D43-0DCE-4322-BC0C-555BE7F19AB7Q33411063-4CB7972C-26D7-452C-B83E-88D4458A3CEAQ33564957-4770012F-590B-4227-8E44-938F7501E548Q33598400-C831F592-7261-4DBF-82A9-B3567B28C65CQ33763285-1A79E219-5962-4300-B707-3431C3848020Q33853564-F4878904-F679-402B-AE5F-A522ABCC3B56Q34005379-EB10AB4B-A720-4B45-A762-671EB2D25D73Q34025054-F6BD62E7-396B-487B-9109-8A8DE560FF5FQ34047653-F916DF6F-DF8F-4FA4-AAFF-43740FBFD27BQ34086102-61EA13B9-E794-4CE5-B431-887C95071000Q34130897-8121204C-F41D-43C8-AB05-79716F198A7DQ34303009-13E12F92-8FD6-4B4C-9558-A585B0019BA3Q34321255-919BCA5C-EDCE-4087-BF4A-8430017E640CQ34397357-A1F2E01D-4584-4BE9-9FC9-5A32D78A9C3AQ34403155-8595FFB1-B5A6-4024-B3BF-02C61C04CD71Q34408967-C817D0D6-4266-4C9E-9874-A6FAAA2B4B6CQ34410667-67F472FC-F4E5-4659-B068-A39F86D919B9Q34433948-DC7FD916-CBA7-415A-A162-6C402AE3510DQ34437920-759273E6-E9C5-44D8-BAC9-728472AD605FQ34518393-F98734E4-5D1D-4376-9FCC-AEA723FDE7E9Q34562131-C626C3F5-7FA2-462C-B73B-65A45716AB12Q34585315-1EB91091-B36F-42D9-B907-18CFE10A6E71Q34585397-7DBE0F7A-0FDF-4D28-8724-C98B9A6C4189Q34639710-1D7BBD0A-953E-4EC6-B127-3EA2C8010AC3Q34669225-D779AC57-65EF-40D2-8B37-CF5BFFD579F0Q34996559-ECD4941A-4B42-4EC5-92AE-1130E5A40CC1Q35048681-116D8AB1-4428-4B77-8786-716D8BF61959Q35145017-614818AE-305D-46E5-9833-61D770F6179B
P2860
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@en
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@nl
type
label
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@en
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@nl
prefLabel
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@en
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@nl
P2093
P921
P1476
Methotrexate induces clinical ...... ry inflammatory bowel disease.
@en
P2093
P304
P356
10.7326/0003-4819-110-5-353
P407
P577
1989-03-01T00:00:00Z